向“新”而行 “中国医药城”通化谋千亿大产业

Core Viewpoint - The pharmaceutical industry in Tonghua City is rapidly developing, leveraging innovative drugs to enhance productivity and aiming for a total industry output value of 100 billion yuan by 2026 [1][9]. Group 1: Industry Overview - Tonghua City is recognized as China's first "Pharmaceutical City," with the pharmaceutical and health industry being its largest pillar, achieving an output value of over 60 billion yuan in 2023 [1][6]. - The city aims to reach a total output value of 100 billion yuan in the pharmaceutical health industry by 2026, focusing on optimizing and upgrading the industry structure [1][9]. Group 2: Company Developments - Anruite Biopharmaceutical Co., Ltd. has launched the first phase of its recombinant human albumin injection production base, with an annual production capacity of 50 tons, and plans to expand to 600 tons in the next 3 to 5 years [2][3]. - Tonghua Dongbao, a leading company in the insulin industry, is advancing the development of innovative drugs, including a dual-target receptor agonist for diabetes treatment, which has entered clinical trials [4]. Group 3: Market Demand and Supply - The estimated demand for albumin in the Chinese market is around 720 tons, with approximately 60% currently imported, highlighting the significance of Anruite's product in addressing supply chain vulnerabilities [3]. - The city is actively encouraging pharmaceutical companies to conduct consistency evaluations for generic drugs, with a total of 28 products expected to complete evaluations by the end of the year [7]. Group 4: Future Goals and Strategies - The city plans to establish a competitive pharmaceutical industry cluster and a base for the transformation and industrialization of pharmaceutical technology achievements by 2026 [9]. - Companies are encouraged to enhance their R&D capabilities and collaborate with various research institutions to drive innovation and product pipeline expansion [9][10]. Group 5: Talent and Investment - The development of new productive forces in the pharmaceutical industry is heavily reliant on talent, with calls for more effective talent policies to attract and retain skilled professionals [11]. - The city is focusing on integrating talent, technology, and funding to support the growth of the pharmaceutical industry, including establishing high-end platforms for technological support [11].